Does ALEMTUZUMAB Cause Hyperlipidaemia? 25 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 25 reports of Hyperlipidaemia have been filed in association with ALEMTUZUMAB (Campath). This represents 0.2% of all adverse event reports for ALEMTUZUMAB.
25
Reports of Hyperlipidaemia with ALEMTUZUMAB
0.2%
of all ALEMTUZUMAB reports
5
Deaths
6
Hospitalizations
How Dangerous Is Hyperlipidaemia From ALEMTUZUMAB?
Of the 25 reports, 5 (20.0%) resulted in death, 6 (24.0%) required hospitalization.
Is Hyperlipidaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ALEMTUZUMAB. However, 25 reports have been filed with the FAERS database.
What Other Side Effects Does ALEMTUZUMAB Cause?
Headache (1,808)
Fatigue (1,744)
Pyrexia (1,441)
Off label use (1,259)
Rash (1,094)
Nausea (1,053)
Dyspnoea (855)
Lymphocyte count decreased (852)
Asthenia (841)
Multiple sclerosis relapse (836)
What Other Drugs Cause Hyperlipidaemia?
ALENDRONATE (511)
AMLODIPINE (226)
DENOSUMAB (204)
SITAGLIPTIN (186)
METHOTREXATE (184)
ROSUVASTATIN (179)
PREDNISONE (169)
FINASTERIDE (145)
MYCOPHENOLATE MOFETIL (141)
ASPIRIN (138)
Which ALEMTUZUMAB Alternatives Have Lower Hyperlipidaemia Risk?
ALEMTUZUMAB vs ALENDRONATE
ALEMTUZUMAB vs ALENDRONATE\CHOLECALCIFEROL
ALEMTUZUMAB vs ALENDRONIC ACID
ALEMTUZUMAB vs ALEVE
ALEMTUZUMAB vs ALEVE CAPLET